JP2013526572A - 眼治療薬の送達のための薬物送達装置 - Google Patents

眼治療薬の送達のための薬物送達装置 Download PDF

Info

Publication number
JP2013526572A
JP2013526572A JP2013511293A JP2013511293A JP2013526572A JP 2013526572 A JP2013526572 A JP 2013526572A JP 2013511293 A JP2013511293 A JP 2013511293A JP 2013511293 A JP2013511293 A JP 2013511293A JP 2013526572 A JP2013526572 A JP 2013526572A
Authority
JP
Japan
Prior art keywords
active agent
rate
polymer compound
drug delivery
delivery device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013511293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526572A5 (https=
Inventor
コプチンスキー，ケーシー
リン，チェン−ウェン
ステイ，クリス
Original Assignee
アエリエ・ファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アエリエ・ファーマシューティカルズ・インコーポレーテッド filed Critical アエリエ・ファーマシューティカルズ・インコーポレーテッド
Publication of JP2013526572A publication Critical patent/JP2013526572A/ja
Publication of JP2013526572A5 publication Critical patent/JP2013526572A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013511293A 2010-05-17 2011-05-17 眼治療薬の送達のための薬物送達装置 Pending JP2013526572A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34554710P 2010-05-17 2010-05-17
US61/345,547 2010-05-17
PCT/US2011/036806 WO2011146483A1 (en) 2010-05-17 2011-05-17 Drug delivery devices for delivery of ocular therapeutic agents

Publications (2)

Publication Number Publication Date
JP2013526572A true JP2013526572A (ja) 2013-06-24
JP2013526572A5 JP2013526572A5 (https=) 2014-07-03

Family

ID=44992020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013511293A Pending JP2013526572A (ja) 2010-05-17 2011-05-17 眼治療薬の送達のための薬物送達装置

Country Status (6)

Country Link
US (6) US20130142858A1 (https=)
EP (1) EP2571526B1 (https=)
JP (1) JP2013526572A (https=)
AU (1) AU2011256259A1 (https=)
CA (1) CA2798084A1 (https=)
WO (1) WO2011146483A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535592A (ja) * 2014-11-25 2017-11-30 エキシモア・リミテッドＥｘｉｍｏｒｅ Ｌｔｄ． 生物活性剤または生物活性剤類を送達する組成物および方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
EP2571526B1 (en) 2010-05-17 2019-03-13 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
ES2992024T3 (es) 2011-06-23 2024-12-05 Dsm Ip Assets Bv Nuevos copolímeros de poliesteramida biodegradables para la administración de fármacos
US9102105B2 (en) * 2011-09-13 2015-08-11 Vista Scientific Llc Method for forming an ocular drug delivery device
JP5989780B2 (ja) 2011-09-14 2016-09-07 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
US20150038415A1 (en) * 2011-12-16 2015-02-05 Dsm Ip Assets B.V. Process for the manufacturing of a drug delivery system based on a polymer comprising a dispersed bioactive agent
US8900300B1 (en) 2012-02-22 2014-12-02 Omega Ophthalmics Llc Prosthetic capsular bag and method of inserting the same
CN104717962B (zh) 2012-10-02 2017-07-21 帝斯曼知识产权资产管理有限公司 包含蛋白质和可生物降解聚酯酰胺的药物递送组合物
RU2652063C2 (ru) 2012-10-26 2018-04-24 Форсайт Вижн5, Инк. Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
WO2014179568A2 (en) 2013-05-02 2014-11-06 Odin Biotech Two-layer ocular implant
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
AU2015277207B2 (en) 2014-06-19 2018-03-29 Omega Ophthalmics Llc Prosthetic capsular devices, systems, and methods
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
US9358103B1 (en) 2015-02-10 2016-06-07 Omega Ophthalmics Llc Prosthetic capsular devices, systems, and methods
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
WO2016187355A1 (en) * 2015-05-20 2016-11-24 Glaukos Corporation Therapeutic drug compositions and implants for delivery of same
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
US9993336B2 (en) 2016-06-06 2018-06-12 Omega Ophthalmics Llc Prosthetic capsular devices, systems, and methods
WO2018075932A1 (en) 2016-10-21 2018-04-26 Omega Ophthalmics Llc Prosthetic capsular devices, systems, and methods
US20200147055A1 (en) * 2017-05-30 2020-05-14 Eximore Ltd. Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide
AU2019249216B2 (en) 2018-04-06 2024-07-18 Omega Ophthalmics Llc Prosthetic capsular devices, systems, and methods
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
CA3160955A1 (en) 2019-11-12 2021-05-20 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures
WO2022082170A1 (en) 2020-10-12 2022-04-21 Omega Ophthalmics Llc Prosthetic capsular devices, systems, and methods
US12186512B2 (en) * 2020-10-26 2025-01-07 Christopher Green Treatment for dry eyes
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
WO2024258996A1 (en) * 2023-06-16 2024-12-19 Baylor College Of Medicine Ocular drug delivery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517425A (ja) * 1997-08-28 2003-05-27 コントロール・デリヴァリー・システムズ，インコーポレイテッド 持続放出型ドラッグデリバリーシステム
JP2006516619A (ja) * 2003-01-24 2006-07-06 コントロール・デリバリー・システムズ・インコーポレイテッド 炭酸脱水酵素阻害剤を眼へ輸送するために徐放性デバイス及び方法
JP2007535537A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド プロスタミド含有生分解性眼内インプラント

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3618604A (en) 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3986510A (en) 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3993071A (en) 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US3981303A (en) 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
SE375007B (https=) 1972-11-30 1975-04-07 Pharmacia Ab
US4177256A (en) 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US3961628A (en) 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US4135514A (en) 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4052505A (en) 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4057619A (en) 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4164560A (en) 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4190642A (en) 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4278087A (en) 1980-04-28 1981-07-14 Alza Corporation Device with integrated operations for controlling release of agent
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4753652A (en) 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
US4663147A (en) 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
CA1330886C (en) 1988-01-22 1994-07-26 Bend Research Inc. Osmotic system for delivery of dilute solutions
US5185152A (en) 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
WO1991017724A1 (en) 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5302397A (en) 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2692812B1 (fr) 1992-06-24 1994-12-30 Flamel Tech Sa Microcapsules contenant au moins un principe actif, leurs applications et procédé de préparation de microcapsules renfermant au moins un principe actif.
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
EP1554990A3 (en) 1999-01-29 2008-08-06 Medtronic, Inc. Implantable medical device with enhanced biocompatibility and biostability
CA2383499C (en) 1999-10-21 2009-11-24 Alcon Universal Ltd. Drug delivery device
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
JP4184082B2 (ja) * 2001-01-03 2008-11-19 ボシュ・アンド・ロム・インコーポレイテッド 複数の薬剤を備えた徐放薬剤送達装置
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
WO2003020172A1 (en) 2001-08-29 2003-03-13 De Carvalho Ricardo A P An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
US20030059466A1 (en) 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
US20060167435A1 (en) 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
US20050079199A1 (en) 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
DE602004026173D1 (de) 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
NZ575950A (en) 2003-11-13 2010-06-25 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
US7211272B2 (en) 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
US20070053963A1 (en) 2004-01-13 2007-03-08 Hotchkiss Robert N Drug delivery to a joint
GB0401947D0 (en) 2004-01-28 2004-03-03 Unilever Plc Porous bodies and method of production thereof
SG150501A1 (en) 2004-02-05 2009-03-30 Millipore Corp Porous adsorptive or chromatographic media
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
ATE469924T1 (de) 2004-08-03 2010-06-15 Agency Science Tech & Res Polymer mit miteinander verbundenen poren zur arzneistoffzufuhr und verfahren
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US20060247266A1 (en) * 2004-11-26 2006-11-02 Asahi Kasei Pharma Corporation Nitrogen-containing tricyclic compounds
US20060134174A1 (en) 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20070009564A1 (en) 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20070212397A1 (en) 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
DE602006005826D1 (de) * 2005-09-21 2009-04-30 Univ Aston Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primärem glaukom
US20070260203A1 (en) 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080057102A1 (en) 2006-08-21 2008-03-06 Wouter Roorda Methods of manufacturing medical devices for controlled drug release
CN102046147B (zh) 2007-06-06 2013-03-20 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制剂
DE102008012295A1 (de) 2008-03-03 2009-09-17 Südzucker AG Mannheim/Ochsenfurt Gemisch zur Herstellung von schnell zerfallenden Tabletten
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100158980A1 (en) 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
WO2011079232A1 (en) 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
CA2795706A1 (en) 2010-04-06 2011-10-13 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
EP2571526B1 (en) 2010-05-17 2019-03-13 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517425A (ja) * 1997-08-28 2003-05-27 コントロール・デリヴァリー・システムズ，インコーポレイテッド 持続放出型ドラッグデリバリーシステム
JP2006516619A (ja) * 2003-01-24 2006-07-06 コントロール・デリバリー・システムズ・インコーポレイテッド 炭酸脱水酵素阻害剤を眼へ輸送するために徐放性デバイス及び方法
JP2007535537A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド プロスタミド含有生分解性眼内インプラント

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535592A (ja) * 2014-11-25 2017-11-30 エキシモア・リミテッドＥｘｉｍｏｒｅ Ｌｔｄ． 生物活性剤または生物活性剤類を送達する組成物および方法

Also Published As

Publication number Publication date
EP2571526A4 (en) 2014-06-25
US20230094779A1 (en) 2023-03-30
US20130317458A1 (en) 2013-11-28
US10869833B2 (en) 2020-12-22
US20160106667A1 (en) 2016-04-21
EP2571526B1 (en) 2019-03-13
EP2571526A1 (en) 2013-03-27
US8765166B2 (en) 2014-07-01
US9808420B2 (en) 2017-11-07
US20210251892A1 (en) 2021-08-19
US20180228725A1 (en) 2018-08-16
AU2011256259A1 (en) 2012-11-08
US20130142858A1 (en) 2013-06-06
WO2011146483A1 (en) 2011-11-24
CA2798084A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
US20230094779A1 (en) Drug delivery devices for delivery of ocular therapeutics agents
JP2012512904A (ja) 治療薬の送達のための薬物送達装置
US6991808B2 (en) Process for the production of sustained release drug delivery devices
EP1404295B1 (en) Sustained release drug delivery devices with coated drug cores
JP4705304B2 (ja) 徐放性薬剤送達システム、使用方法、およびその製造方法
CA2301685C (en) Sustained release drug delivery devices
US20070212397A1 (en) Pharmaceutical delivery device and method for providing ocular treatment
JP2013523334A (ja) 治療薬を制御放出するための涙点プラグ
MX2007003789A (es) Suministro ocular de formulaciones polimericas para suministro.
JP2003515528A (ja) ドラッグデリバリ製剤
TW201210581A (en) Porous matrix drug core for lacrimal insert device
Nair et al. Current trends in ocular drug delivery systems and its applications
Ara et al. Occular Drug Delivery System: An Overview
EP1847255A2 (en) Sustained release drug delivery devices with coated drug cores

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150616